지혈기 시장 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of hemostats Market

The global hemostats market was valued at USD 5.46 billion in 2025 and is projected to grow to USD 5.86 billion in 2026. The market is expected to reach USD 11.04 billion by 2034, registering a CAGR of 8.23% during 2026-2034.

North America dominated the global market in 2025, accounting for a 34.96% share, driven by high surgical volumes and rapid adoption of advanced hemostatic products.

Introduction

Hemostats are critical medical products used to control bleeding during surgical procedures. They play an essential role in improving surgical outcomes by minimizing blood loss and reducing complications. With the growing burden of chronic diseases such as cardiovascular disorders, cancer, and trauma cases, the demand for effective bleeding control solutions is rising globally.

Market Trends

A major trend in the market is the increasing number of hospitals and surgical centers worldwide. The expansion of healthcare infrastructure is leading to a higher volume of surgeries, thereby increasing the demand for hemostatic agents.

Additionally, the continuous introduction of advanced and absorbable hemostatic products is improving clinical efficiency and driving adoption across healthcare facilities.

Market Growth Drivers

1. Rising Number of Surgical Procedures

Globally, the number of surgeries is increasing significantly. Estimates suggest that around 310 million major surgeries are performed annually. This rise directly increases the demand for hemostats to manage bleeding complications effectively.

2. Growing Prevalence of Chronic Diseases

The increasing incidence of cardiovascular diseases, cancer, and other chronic conditions is leading to more surgical interventions. This trend is a major factor contributing to market growth.

3. Technological Advancements

Innovations in hemostatic products, such as fibrin sealants and polysaccharide-based agents, are enhancing efficiency and reducing infection risks. These advancements are expanding the application scope of hemostats.

4. Increase in Trauma and Accident Cases

The rising number of accidents and trauma cases globally is further driving the need for surgical procedures and, consequently, hemostatic products.

Market Restraints

Despite strong growth, the market faces certain challenges:

• High costs of advanced hemostatic products
• Clinical limitations in cases of severe or uncontrolled bleeding
• Restricted adoption in cost-sensitive healthcare systems

These factors may hinder widespread market penetration.

Market Segmentation

By Product

• Passive Hemostats: Dominated the market and are expected to hold a 48.21% share in 2026, due to wide availability and strong clinical acceptance.
• Active Hemostats: Include thrombin-based and fibrin sealants.
• Combination Hemostats: Expected to grow at the fastest rate due to advanced product innovations.

By Application

• General Surgery: Leading segment with a 21.91% share in 2026, driven by the high volume of procedures.
• Other applications include cardiovascular surgery, trauma, orthopedic, neurosurgery, and plastic surgery.
• Cardiovascular surgery is expected to witness the fastest growth due to increasing heart-related conditions.

By End-User

• Hospitals & Ambulatory Surgical Centers (ASCs): Dominated with an 89.38% share in 2026, as most surgeries are conducted in these settings.
• Other segments include tactical combat casualty care centers and specialty clinics.

Regional Insights

• North America: Largest market with USD 1.91 billion in 2025, projected to reach USD 2.04 billion in 2026, driven by advanced healthcare infrastructure and high surgical volumes.
• Europe: Valued at USD 1.47 billion in 2025, expected to grow to USD 1.55 billion in 2026, supported by strong healthcare spending.
• Asia Pacific: Reached USD 1.34 billion in 2025, projected to reach USD 1.47 billion in 2026, driven by increasing surgeries and healthcare expansion.
• Latin America: Valued at USD 0.45 billion in 2025, expected to reach USD 0.49 billion in 2026.
• Middle East & Africa: Accounted for USD 0.29 billion in 2025, projected to reach USD 0.31 billion in 2026.

Competitive Landscape

The market is moderately consolidated, with major players such as Baxter, Ethicon (Johnson & Johnson), and BD (Becton, Dickinson and Company) leading due to strong product portfolios and continuous innovation.

Other key players include Integra LifeSciences, Stryker, Medtronic, Pfizer, and Biom'up. These companies focus on product launches, acquisitions, and regulatory approvals to strengthen their market presence.

Conclusion

The hemostats market is poised for robust growth, expanding from USD 5.46 billion in 2025 to USD 11.04 billion by 2034. The growth is primarily driven by the increasing number of surgical procedures, rising prevalence of chronic diseases, and continuous advancements in medical technologies.

Although high costs and clinical limitations pose challenges, the growing demand for effective bleeding management solutions and expanding healthcare infrastructure will sustain market expansion. Hemostats will continue to play a vital role in improving surgical safety and patient outcomes across the global healthcare industry.

Segmentation By Product

• Active Hemostats
  • Thrombin Based Hemostats
  • Fibrin Sealants
• Passive Hemostats
  • Plant-based Hemostats
  • Animal-based Hemostats
  • Others
• Combination Hemostats
• Others

By Application

• Trauma
• Cardiovascular Surgery
• General Surgery
• Plastic Surgery
• Orthopedic Surgery
• Neurosurgery
• Others

By End-User

• Hospitals & ASCs
• Tactical Combat Casualty Care Centers
• Others

By Region

• North America (By Product, Application, End-User, and Country)
  • U.S.
  • Canada
• Europe (By Product, Application, End-User, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, Application, End-User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, Application, End-User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, Application, End-User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Key Surgical Procedures, By Key Countries/Regions, 2025/2025
• 4.2. Epidemiology of Key Diseases, By Key Countries/Regions
• 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.4. New Product Launches, By Key Players
• 4.5. Impact of COVID-19 on the Market

5. Global Hemostats Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Active Hemostats
    • 5.1.1.1. Thrombin-based Hemostats
    • 5.1.1.2. Fibrin Sealants
  • 5.1.2. Passive Hemostats
    • 5.1.2.1. Plant-based Hemostats
    • 5.1.2.2. Animal-based Hemostats
    • 5.1.2.3. Others
  • 5.1.3. Combination Hemostats
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Trauma
  • 5.2.2. Cardiovascular Surgery
  • 5.2.3. General Surgery
  • 5.2.4. Plastic Surgery
  • 5.2.5. Orthopedic Surgery
  • 5.2.6. Neurosurgery
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals & ASCs
  • 5.3.2. Tactical Combat Casualty Care Centers
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East and Africa

6. North America Hemostats Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Active Hemostats
    • 6.1.1.1. Thrombin-based Hemostats
    • 6.1.1.2. Fibrin Sealants
  • 6.1.2. Passive Hemostats
    • 6.1.2.1. Plant-based Hemostats
    • 6.1.2.2. Animal-based Hemostats
    • 6.1.2.3. Others
  • 6.1.3. Combination Hemostats
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Trauma
  • 6.2.2. Cardiovascular Surgery
  • 6.2.3. General Surgery
  • 6.2.4. Plastic Surgery
  • 6.2.5. Orthopedic Surgery
  • 6.2.6. Neurosurgery
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals & ASCs
  • 6.3.2. Tactical Combat Casualty Care Centers
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast- By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Hemostats Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Active Hemostats
    • 7.1.1.1. Thrombin-based Hemostats
    • 7.1.1.2. Fibrin Sealants
  • 7.1.2. Passive Hemostats
    • 7.1.2.1. Plant-based Hemostats
    • 7.1.2.2. Animal-based Hemostats
    • 7.1.2.3. Others
  • 7.1.3. Combination Hemostats
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Trauma
  • 7.2.2. Cardiovascular Surgery
  • 7.2.3. General Surgery
  • 7.2.4. Plastic Surgery
  • 7.2.5. Orthopedic Surgery
  • 7.2.6. Neurosurgery
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals & ASCs
  • 7.3.2. Tactical Combat Casualty Care Centers
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. UK
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Hemostats Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Active Hemostats
    • 8.1.1.1. Thrombin-based Hemostats
    • 8.1.1.2. Fibrin Sealants
  • 8.1.2. Passive Hemostats
    • 8.1.2.1. Plant-based Hemostats
    • 8.1.2.2. Animal-based Hemostats
    • 8.1.2.3. Others
  • 8.1.3. Combination Hemostats
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Trauma
  • 8.2.2. Cardiovascular Surgery
  • 8.2.3. General Surgery
  • 8.2.4. Plastic Surgery
  • 8.2.5. Orthopedic Surgery
  • 8.2.6. Neurosurgery
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals & ASCs
  • 8.3.2. Tactical Combat Casualty Care Centers
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia & New Zealand
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Hemostats Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Active Hemostats
    • 9.1.1.1. Thrombin-based Hemostats
    • 9.1.1.2. Fibrin Sealants
  • 9.1.2. Passive Hemostats
    • 9.1.2.1. Plant-based Hemostats
    • 9.1.2.2. Animal-based Hemostats
    • 9.1.2.3. Others
  • 9.1.3. Combination Hemostats
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Trauma
  • 9.2.2. Cardiovascular Surgery
  • 9.2.3. General Surgery
  • 9.2.4. Plastic Surgery
  • 9.2.5. Orthopedic Surgery
  • 9.2.6. Neurosurgery
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals & ASCs
  • 9.3.2. Tactical Combat Casualty Care Centers
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East and Africa Hemostats Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Active Hemostats
    • 10.1.1.1. Thrombin-based Hemostats
    • 10.1.1.2. Fibrin Sealants
  • 10.1.2. Passive Hemostats
    • 10.1.2.1. Plant-based Hemostats
    • 10.1.2.2. Animal-based Hemostats
    • 10.1.2.3. Others
  • 10.1.3. Combination Hemostats
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Trauma
  • 10.2.2. Cardiovascular Surgery
  • 10.2.3. General Surgery
  • 10.2.4. Plastic Surgery
  • 10.2.5. Orthopedic Surgery
  • 10.2.6. Neurosurgery
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals & ASCs
  • 10.3.2. Tactical Combat Casualty Care Centers
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Baxter
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT analysis
    • 11.2.1.4. Recent developments
    • 11.2.1.5. strategies
    • 11.2.1.6. financials (based on availability)
  • 11.2.2. Integra Life Sciences
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT analysis
    • 11.2.2.4. Recent developments
    • 11.2.2.5. strategies
    • 11.2.2.6. financials (based on availability)
  • 11.2.3. Stryker
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT analysis
    • 11.2.3.4. Recent developments
    • 11.2.3.5. strategies
    • 11.2.3.6. financials (based on availability)
  • 11.2.4. Artivion, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT analysis
    • 11.2.4.4. Recent developments
    • 11.2.4.5. strategies
    • 11.2.4.6. financials (based on availability)
  • 11.2.5. BD
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT analysis
    • 11.2.5.4. Recent developments
    • 11.2.5.5. strategies
    • 11.2.5.6. financials (based on availability)
  • 11.2.6. Pfizer Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT analysis
    • 11.2.6.4. Recent developments
    • 11.2.6.5. strategies
    • 11.2.6.6. financials (based on availability)
  • 11.2.7. Medtronic
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT analysis
    • 11.2.7.4. Recent developments
    • 11.2.7.5. strategies
    • 11.2.7.6. financials (based on availability)
  • 11.2.8. Biom'up
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT analysis
    • 11.2.8.4. Recent developments
    • 11.2.8.5. strategies
    • 11.2.8.6. financials (based on availability)
  • 11.2.9. Johnson & Johnson Services, Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT analysis
    • 11.2.9.4. Recent developments
    • 11.2.9.5. strategies
    • 11.2.9.6. financials (based on availability)